Annalisa Jenkins is a life-sciences thought leader with over 25 years of experience in the industry. She studied medicine at the University of London, received her Fellowship of the Royal College of Physicians and later specialised in cardiology. Earlier in her career, Annalisa was a medical officer in the Royal Navy during the Gulf War, achieving the rank of surgeon lieutenant commander. She held senior roles at Merck Serono and Bristol Myers-Squibb before becoming president and chief executive officer of Dimension Therapeutics, which she took public and later sold to Ultragenyx.
Annalisa currently holds roles spanning the public, private and charitable sectors, including at Genomics England, the King's Fund and the British Heart Foundation. She is also on the boards of growing biotech companies Oncimmune, COMPASS Pathways and Mereo Biopharma, among others. Annalisa contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.